AVANIR Regains Compliance with NASDAQ Listing Requirements

ALISO VIEJO, Calif., April 21, 2008AVANIR Pharmaceuticals (NASDAQ: AVNR) today announced that it has received notification from NASDAQ that it has regained compliance with listing standards required to maintain its listing on the NASDAQ Global Market.

As previously reported on March 27, 2008, AVANIR received notification from NASDAQ that the market value of the Company's listed securities had been below $50 million for the previous 10 consecutive trading days and therefore had fallen out of compliance with continued listing requirements for the NASDAQ Global Market. On April 7, 2008, the Company completed a $40 million offering of common stock and warrants to a select group of institutional investors, which allowed AVANIR to regain compliance with NASDAQ standards.

The proceeds from this offering will be used to fund the confirmatory Phase III STAR trial of the investigational drug Zenvia (dextromethorphan/quinidine) and submit a complete response to the FDA approvable letter for the pseudobulbar affect (PBA) indication. Top-line PBA data from the STAR trial are expected in the second half of calendar year 2009 with a complete response expected to be submitted to the FDA in the first half of calendar year 2010. Offering proceeds will also be used for general working capital.


AVANIR Pharmaceuticals is focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, inflammation, and infectious diseases. AVANIR's lead product candidate, Zenvia, is being developed for the treatment of pseudobulbar affect (PBA) and is the subject of an approvable letter from the FDA for that indication. The Company has initiated a confirmatory Phase III study under a Special Protocol Assessment (SPA) agreement with the FDA utilizing a new lower quinidine dose formulation of Zenvia intended to address safety concerns raised in the Agency's approvable letter for Zenvia in the treatment of PBA. Additionally, in April 2007 AVANIR announced meeting all primary endpoints in a Phase III clinical trial with Zenvia in patients with diabetic peripheral neuropathic (DPN) pain. The Company is conducting a formal pharmacokinetic (PK) study to assess alternative lower-dose quinidine formulations of Zenvia for DPN pain that are intended to deliver similar efficacy and improve safety/tolerability versus the formulations previously tested for this indication. AVANIR has licensed the MIF inhibitor program to Novartis International Pharmaceuticals Ltd and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

Forward-Looking Statements

Statements in this press release that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," or similar statements, are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. There can be no assurance that any additional Phase III trial for Zenvia will be successful, that any new doses of Zenvia will be safe and effective, or that the U.S. Food and Drug Administration (FDA) will approve Zenvia for any indication. There can also be no assurance that the proceeds from the recently closed offering will be sufficient to fund our clinical trials to completion as expected or to fund operations through the expected timing of an approval decision from the FDA. Risks and uncertainties affecting the Company's financial condition and operations also include the risks set forth in AVANIR's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time-to-time in other publicly available information regarding the Company. Copies of this information are available from AVANIR upon request. AVANIR disclaims any intent to update these forward-looking statements.

To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0.

AVANIR Investor Contacts
Eric Benevich
Brenna Mullen
(949) 389-6700

Apr 21, 2008